CD19 and non-Hodgkin lymphoma: The meta-analysis presented here provides a comprehensive evaluation of the efficacy and safety of autologous/allogeneic DNA transposon-CD19 CAR T-cell therapy across 110 patients with relapsed/refractory B-ALL, B-NHL, and CLL.